PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,943 | -34.0% | 127,843 | -15.5% | 0.18% | -21.9% |
| Q2 2023 | $5,978 | +226.7% | 151,277 | +222.1% | 0.24% | +233.8% |
| Q4 2022 | $1,830 | -99.9% | 46,971 | +102.0% | 0.07% | -24.5% |
| Q3 2022 | $1,262,000 | -86.9% | 23,250 | -85.8% | 0.09% | -78.0% |
| Q2 2022 | $9,633,000 | -36.7% | 164,250 | -18.3% | 0.43% | -19.5% |
| Q1 2022 | $15,227,000 | +42.1% | 201,143 | +14.5% | 0.53% | +54.2% |
| Q4 2021 | $10,714,000 | +6.5% | 175,693 | -1.0% | 0.34% | +5.8% |
| Q3 2021 | $10,062,000 | -6.6% | 177,493 | 0.0% | 0.33% | -10.7% |
| Q2 2021 | $10,773,000 | -12.4% | 177,493 | +2.2% | 0.36% | -23.3% |
| Q1 2021 | $12,292,000 | +2.4% | 173,693 | -15.0% | 0.48% | -8.3% |
| Q4 2020 | $12,003,000 | +41.8% | 204,330 | +43.2% | 0.52% | +7.0% |
| Q3 2020 | $8,467,000 | +213.0% | 142,674 | +176.5% | 0.48% | +188.7% |
| Q2 2020 | $2,705,000 | – | 51,600 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |